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Abstract: Inﬂ  iximab is a monoclonal antibody that targets tumor necrosis factor-α (TNFα). 
It is used in the treatment of a number of inﬂ  ammatory disorders including severe plaque 
psoriasis. TNFα is thought to have a major role in psoriasis by promoting an inﬂ  ammatory 
inﬁ  ltrate into the skin and inducing keratinocyte proliferation and preventing keratinocyte 
apoptosis, which directly contributes to the characteristic plaque skin lesions. Based on four 
randomized, placebo-controlled, double-blind clinical trials and nine open-label uncontrolled 
trials of the use of inﬂ  iximab in plaque psoriasis, it was found that inﬂ  iximab is a highly 
efﬁ  cacious, rapid, sustainable, and relatively safe therapy. Yet as with any biologic, caution is 
recommended in its use as infusion reactions, lupus-like syndromes, infections, malignancies 
including lymphomas, as well as other rare events have been reported.
Keywords: inﬂ  iximab, psoriasis, plaque
Psoriasis is a chronic inﬂ  ammatory disease of the skin affecting at least 5.8 million 
people in the United States and 125 million people worldwide (National Psoriasis 
Foundation 2007; Gelfand et al 2005). The most common form of psoriasis, psoriasis 
vulgaris, occurs in more than 80% of cases. Less common forms include guttate pso-
riasis and erythrodermic and pustular psoriasis, which occur in approximately 10% 
and 3% of patients, respectively (Lebwohl 2003). Psoriatic lesions may be pruritic and 
disﬁ  guring, resulting in a signiﬁ  cant negative physical and emotional impact in those 
affected. Feelings of depression, fear and embarrassment, as well as dissatisfaction 
with disease management, are widespread among persons suffering from psoriasis 
(Krueger et al 2001). In 10%–30% of psoriatic patients, nail dystrophy and psoriatic 
arthritis cause interference with many daily activities that require both ﬁ  ne and gross 
motor skills (Nickoloff and Nestle 2004). Psoriasis cannot be explained purely by 
genetics (Elder et al 2001) or environment; it has a complex immunopathology that 
is not fully understood.
Immunopathology of psoriasis
Psoriasis results from an abnormal activation of the immune system, with T cells in 
the epidermis and dermis playing a central role. The initial activation of T cells is 
unclear, but is thought to be due to a protuberance in epidermal keratinocytes from 
exogenous stimuli such as trauma and UV exposure, or endogenous stimuli such 
as infection and medications (eg, lithium and β-blockers) which through a “danger 
signal” leads to the activation of antigen presenting cells (APCs) such as Langerhans 
cells (Matzinger 2002; Nickoloff and Nestle 2004). Once activated, Langerhans cells 
migrate through the lymphatic system to surrounding lymph nodes where its MHC-
antigen complex is recognized by speciﬁ  c T cell receptors on naïve T cells. Full activa-
tion of T cells occurs with a costimulatory molecule on APCs combining with CD28 
on T cells. The activated T cell expresses cutaneous lymphocyte-associated antigen 
(CLA) which allows access to the skin (Langley et al 2007). The abnormally activated Biologics: Targets & Therapy 2008:2(1) 116
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T cells elaborate cytokines including tumor necrosis factor-α 
(TNFα) and γ-interferon which contribute to a vicious cycle 
of inﬂ  ammation and tissue damage, manifested clinically as 
plaque skin lesions (Nickoloff 1991).
Role of TNFα in psoriasis
TNFα is found in high concentrations in the skin lesions and 
plasma of patients with psoriasis and has a major role in the 
stimulation and propagation of immunological activity by 
targeting an inﬂ  ammatory inﬁ  ltrate into the skin (Turbitt et al 
1990). TNFα upregulates the expression of vascular endo-
thelial growth factor (VEGF) and intercellular adhesion mol-
ecule-1/vascular cell adhesion molecule-1 which promotes 
angiogenesis and microvascular permeability and targeting of 
lymphocytes to inﬂ  ammatory lesions, respectively (Markham 
et al 2006). TNFα induces Langerhans cell maturation and 
migration to lymph nodes for further T cell activation and 
CLA expression. TNFα further stimulates lymphocyte migra-
tion, increasing the expression of many proinﬂ  ammatory 
cytokines including CCL27 (a skin-speciﬁ  c memory T cell 
attractant) and NF-kB (a ubiquitous transcription factor) that 
leads to the expression of many gene products that mediate 
inﬂ  ammatory responses (Banno et al 2004).
TNFα directly contributes to the characteristic plaque 
surmounted by silvery scales by inducing keratinocyte prolif-
eration and preventing keratinocyte apoptosis via increasing 
vasoactive intestinal peptide (VIP) receptor and increasing 
plasminogen activator inhibitor type 2, a serine protease 
inhibitor, respectively (Gottlieb 2003).
The advances in the understanding of T cells and spe-
ciﬁ  cally TNFα in psoriasis has led to the development of 
biologic agents that target them (Sauder and Mamelak 2004; 
Chong and Wong 2007; Langley et al 2007).
Inﬂ  iximab
Inﬂ  iximab is a chimeric monoclonal antibody comprised of 
human antibody constant regions and murine variable regions 
that was developed to speciﬁ  cally target TNFα. Inﬂ  iximab 
binds both soluble and membrane-bound TNFα, preventing 
it from binding its receptor which results in a decrease in 
epidermal T cell inﬁ  ltration. There is a signiﬁ  cant reduction 
of T cells in the epidermis of psoriatic lesions after 48 hours 
of treatment with a single, low dose (3 mg/kg) infusion of 
inﬂ  iximab (Goedkoop et al 2004).
Inﬂ  iximab helps to control angiogenesis, a key factor in 
the proinﬂ  ammatory state of psoriasis, by down-regulating 
angiopoietin, a growth factor critical for new blood ves-
sel growth, and its receptor, Tie2 (Markham et al 2006). 
Furthermore, anti-TNFα drugs like inﬂ  iximab have been 
shown to restore neuroendocrine pathways (eg, hypotha-
lamic – pituitary – adrenal axis) from the pro-inﬂ  ammatory 
state that TNFα favors, and normalizes hormone levels 
(Straub et al 2006).
Complementary to its anti-inﬂ  ammatory effect that is 
mediated through the neutralization of TNFα, inﬂ  iximab 
normalizes keratinocyte differentiation (Gottlieb et al 2003) 
and induces apoptosis of lesional keratinocytes through a 
caspase independent mechanism to further speed clinical 
improvement (ten Hove et al 2002; Kruger-Krasagakis et al 
2006).
Inﬂ  iximab is used to treat a number of inﬂ  ammatory 
disorders including rheumatoid arthritis, Crohn’s disease, 
and psoriatic arthritis (Markham and Lamb 2000; Woolacott 
et al 2006; Behm and Bickston 2007). In September 2006, 
the US FDA approved the use of inﬂ  iximab in adults with 
chronic, severe plaque psoriasis (FDA 2006). This paper 
aims to review the efﬁ  cacy and safety of inﬂ  iximab in this 
setting based on a plethora of recently published research 
on the topic.
Randomized, placebo-controlled, 
double-blind clinical trials
Four randomized, controlled trials of inﬂ  iximab in the treatment 
of plaque psoriasis have been reported in the literature (Table 1). 
Chaudhari and colleagues (Chaudhari et al 2001; Gottlieb et al 
2003) conducted a small (n  =  33), phase II trial consisting of 
a patient population with moderate to severe plaque psoriasis 
involving a minimum of 5% body surface area (BSA) for 
at least 6 months. The patients were randomly assigned to 
one of three groups: 5 mg/kg inﬂ  iximab (n = 11), 10 mg/kg 
inﬂ  iximab (n = 11), or placebo (n = 11). Infusions were given 
at 0, 2, and 6 weeks and followed by an open-label phase from 
weeks 10–26 in which relapsing patients were retreated as 
needed and placebo nonresponders were given an induction 
of inﬂ  iximab. Beginning at week 2, the improvement in PASI 
(Psoriasis Area and Severity Index) scores were signiﬁ  cantly 
(p   0.0003) higher in both inﬂ  iximab treated groups. At week 
10, the PASI 75 (at least 75% improvement from baseline in 
PASI) was achieved in 82% and 73% of patients receiving 5 
mg/kg and 10 mg/kg inﬂ  iximab, respectively, compared to only 
18% of placebo patients (p   0.05). PASI 75 was maintained 
in 33% and 67% of the respective inﬂ  iximab patients through 
week 26. Infusion reactions occurred in 9% of patients, but 
no other autoimmune events were reported. Reported adverse 
events (AE) were considered mild by the investigator and no 
serious adverse events (SAE) occurred.Biologics: Targets & Therapy 2008:2(1) 117
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A larger (n = 249) phase II trial was conducted by Gottlieb 
and colleagues (Gottlieb et al 2004; Feldman et al 2005) that 
consisted of a study population with severe plaque psoriasis 
covering at least 10% BSA for 6 months or more and a PASI 
of at least 12. Patients were randomly assigned to either a 
3 mg/kg inﬂ  iximab (n = 99), 5 mg/kg inﬂ  iximab (n = 99), 
or placebo (n = 51) treatment group with infusions given at 
0, 2, 6 weeks, and an additional one at week 26 if a static 
Physician’s Global Assessment (PGA) of moderate to severe 
psoriasis was made. At week 10, PASI 75 was achieved in 
72% and 88% of 3 mg/kg and 5 mg/kg inﬂ  iximab patients, 
respectively, compared to only 6% of placebo treated patients 
(p   0.001). In two of the aforementioned studies (Chaudhari 
et al 2001; Gottlieb et al 2004), no signiﬁ  cant differences 
were recorded between the two inﬂ  iximab groups in induc-
ing signiﬁ  cant clearance, but larger dose inﬂ  iximab groups, 
10 mg/kg and 5 mg/kg, respectively, maintained remission 
longer. The Dermatology Life Quality Index (DLQI) at week 
10 was improved by 84% and 91%, respectively, in inﬂ  ix-
imab treated patients compared to 0% in the placebo group 
(p   0.001). AE and SAE were reported in 78% and 4% of 
the 3 mg/kg patients, 79% and 8% of the 5 mg/kg patients, 
and 63% and 0% of the placebo patients, respectively. The 
lower percentage of AE in the placebo group could be partly 
a result of the high dropout rate in the placebo group and 
thus shorter follow-up. Yet four of the SAE in the inﬂ  iximab 
groups – squamous cell carcinoma, cholecystitis and chole-
lithiasis, diverticulitis, and sepsis and pyelonephritis – were 
considered by the investigator to be reasonably related to 
inﬂ  iximab therapy. Infusion reactions were reported in 18% 
and 22% of patients in the inﬂ  iximab groups, respectively, 
compared to 2% of the placebo group. Through week 26, 
24% patients with antibodies to inﬂ  iximab experienced infu-
sion reactions compared to 22% antibody-negative patients 
The only noteworthy elevated lab values were the liver 
function tests (LFTs) aminotransferase (ALT) and aspartate 
aminotransferase (AST) in the inﬂ  iximab groups (34% and 
24%, respectively) compared to placebo (16% and 14%, 
respectively)
Reich et al (2005) reported the ﬁ  rst multicenter phase 
III study of inﬂ  iximab [European Inﬂ  iximab for Psoriasis 
(Remicade) Efﬁ  cacy and Safety Study/EXPRESS] in patients 
(n = 378) with moderate to severe plaque psoriasis of at least 
10% BSA and 6 month duration with PASI of 12 or more. 
Patients were randomly placed into a 5 mg/kg inﬂ  iximab or 
placebo group with infusions given at 0, 2, and 6 weeks and 
then every 8 weeks through week 46. At week 24, placebo 
patients were crossed to receive inﬂ  iximab. At week 10 and 
24, PASI 75 was achieved in 80% and 82% of inﬂ  iximab 
patients, but only 3% and 4% of placebo patients, respectively 
(p   0.0001). At week 50, PASI 75 was achieved in 61% of 
inﬂ  iximab-treated patients. There was generally good toler-
ability to inﬂ  iximab with AE and SAE at week 24 reported in 
82% and 6% of inﬂ  iximab-treated patients and 71% and 3% 
placebo-treated patients, respectively. With equal follow-up, 
similar proportions of patients in the inﬂ  iximab and placebo 
groups were diagnosed with infections, but serious infections 
were more prevalent in the inﬂ  iximab group. Malignancies, 
squamous and basal cell carcinomas, occurred in 1% of inf-
liximab-treated patients but 0% in placebo-treated patients. 
In inﬂ  iximab-treated patients, 3% had infusion reactions 
(2% in the placebo-treated patients) and two patients had 
a lupus-like syndrome. No clinically signiﬁ  cant changes in 
hematological values were noted except for asymptomatic 
increases in AST and ALT.
Menter et al (2007) performed the largest phase III trial 
to date (n = 835) with moderate to severe plaque psoriasis 
covering at least 10% BSA and PASI of 12 or more (Evaluation 
of Inﬂ  iximab for Psoriasis in a Remicade Efﬁ  cacy and Safety 
Study/EXPRESS II). Study participants were randomly 
assigned to a 3 mg/kg (n = 313), 5 mg/kg (n = 314), or placebo 
(n = 208) group with infusions at 0, 2, and 6 weeks. At week 
14, the two inﬂ  iximab groups were re-randomized to either 8 
week continuous or intermittent as-needed therapy. At week 
10, PASI 75 was achieved in 70% and 76% of the 3 mg/kg 
and 5 mg/kg inﬂ  iximab-treated patients, respectively, but 
only 2% of placebo-treated patients (p   0.001). At week 50, 
PASI 75 was achieved in 44% of the 3 mg/kg continuous 
group compared to 25% of the intermittent group, and 55% 
of the 5 mg/kg continuous group compared to 38% of the 
intermittent group. At week 10, both inﬂ  iximab groups had a 
signiﬁ  cant improvement in DLQI (p   0.001). AE and SAE at 
week 14 occurred in 63% and 1.0% of the 3 mg/kg inﬂ  iximab 
group and 69% and 2.9% of the 5 mg/kg inﬂ  iximab group 
compared to 56% and 2.4% of the placebo group, respectively. 
Through week 14, 12% and 10%, in the inﬂ  iximab groups, 
respectively, experienced an infusion reaction compared to 6% 
in the placebo group. While the majority of antibody-positive 
patients did not have an infusion reaction, an increased risk of 
a reaction was present in these patients compared to antibody-
negative patients. Two cases of lupus-like syndrome occurred 
in the inﬂ  iximab group compared to one in the placebo group 
(2:1 randomization of inﬂ  iximab to placebo). Infection rates 
were similar in inﬂ  iximab and placebo groups. Noteworthy 
adverse events in the inﬂ  iximab group involved 2 cases 
of TB, 12 malignancies (1 breast carcinoma, 1 salpingeal Biologics: Targets & Therapy 2008:2(1) 119
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adenocarcinoma, 1 squamous cell skin carcinoma, and 9 basal 
cell skin carcinomas) compared to 0 in the placebo group, and 
a signiﬁ  cant elevation of ALT and AST in fewer than 5% of 
inﬂ  iximab-treated patients.
Open-label, uncontrolled trials
Nine open-label, uncontrolled trials of 5 mg/kg inﬂ  iximab in 
the treatment of psoriasis have been reported (Table 2). In all 
trials, the majority of patients presented with plaque psoriasis 
but patients with erythrodermic and pustular psoriasis, acro-
dermatitis continua, and psoriatic arthritis are also included, 
and the patient population ranges from n = 7 to n = 73.
Chan and Gebauer (2003) demonstrated that a single 
5 mg/kg infusion provided an average PASI and DLQI 
improvement at week 2 of 69% and 61%, respectively, and 
at week 10 (n = 4) of 89% and 79%, respectively, with no 
SAE reported.
In all the other open label studies 5 mg/kg infusions 
were given at a minimum of 0, 2, and 6 weeks. (Schopf et al 
2002) demonstrated an average PASI improvement of 88% 
(n = 8) at week 14. PASI 75 at week 10 was achieved in 
79% (Cassano et al 2004) and 77% of patients (Smith et al 
2006) in trials consisting of 29 and 23 patients, respectively. 
At week 14, PASI 75 was achieved in 68% of patients in a 
trial of 28 patients (Poulalhon et al 2007). The magnitude of 
clinical improvement in the trials that reported PASI scores 
were similar to the randomized, controlled trials with PASI 
75 at week 10 achieved in 76% to 88% of patients receiving 
5 mg/kg infusions in these trials (Table 1).
Three trials measured improvement on the PGA scale: the 
ﬁ  rst reported 88% of patients achieving almost clear improve-
ment or better (n = 52) (Kalb and Gurske 2005); a second 
reported 75% of patients achieving excellent improvement (n 
= 12) (Ahmad and Rogers 2006); and a third reported 89% 
of patients achieving signiﬁ  cant improvement after 12–14 
weeks of treatment (Haitz and Kalb 2007) .
Krathen et al (2006) reported that 51% of patients experi-
enced no loss of efﬁ  cacy, while 30% of patients experienced 
a loss of efﬁ  cacy, and others discontinued their participation 
in the clinical trials due to adverse events or insurance dif-
ﬁ  culties.
AE were similar to those in the randomized, controlled 
trials with infusion reactions and infections being the most 
prevalent (Table 2). Serious infections included extrapulmo-
nary tuberculosis, cellulitis (Smith et al 2006), sepsis, pneu-
monia, and chronic obstructive pulmonary disease (COPD) 
(Poulalhon et al 2007). Two studies reported elevated LFTs 
(Ahmad and Rogers 2006; Smith et al 2006), and one patient 
with a prior history of fatty liver secondary to methotrexate and 
alcohol was diagnosed with autoimmune hepatitis caused by 
inﬂ  iximab (Smith et al 2006). Reported malignancies included 
single cases of breast cancer (Krathen et al 2006), skin cancer, 
metastatic renal cell carcinoma, and CD30+ cutaneous T cell 
lymphoma (Smith et al 2006). The latter occurred in a 56-year-
old man with a 30-year history of immunosuppressive therapies 
including cyclosporine, methotrexate, alefacept, and fumaric 
acid esters after 3 infusions of inﬂ  iximab.
Efﬁ  cacy
The aforementioned clinical trials (Tables 1 and 2) demonstrate 
that infliximab provides a rapid (as early as 2 weeks) 
(Chaudhari et al 2001), highly efﬁ  cacious, and sustainable 
(up to 50 weeks) therapy especially when given at continuous 
(8-week) maintenance intervals (Menter et al 2007) for the 
treatment of moderate to severe plaque psoriasis. Inﬂ  iximab 
use leads to a signiﬁ  cant improvement in the quality of life 
as assessed by DLQI in those affected by psoriasis (Gottlieb 
et al 2004; Menter et al 2007). This is a very important 
ﬁ  nding considering that psoriasis has an impact on an affected 
persons’ physical and mental functioning comparable to that 
seen in cases of cancer, arthritis, hypertension, heart disease, 
diabetes, and depression (Rapp et al 1999).
Safety
Inﬂ  iximab is generally well tolerated; infusion reactions are 
the most commonly reported adverse events, occurring in 
16% inﬂ  iximab-treated patients compared to 6% of placebo-
treated patients (Callen 2007). Infusion-related reactions 
can involve chills, fever, headache, ﬂ  ushing and urticaria, 
myalgia and arthralgia, nausea, dyspnea, and hypotension 
(Gottlieb et al 2004; Reich et al 2005; Menter et al 2007). 
Most infusion-related reactions are mild and usually can be 
ameliorated by reducing rate of infusion rather than discon-
tinuing therapy. A delayed hypersensitivity reaction may 
also present 3–12 days after infusion and produce a serum-
sickness like reaction (Krishnan and Hsu 2004).
Acute and delayed hypersensitivity reactions are partly 
the result of autoantibody formation towards inﬂ  iximab, 
a concern related to the infusion of any foreign protein 
(Schellekens 2002). Patients with inﬂ  iximab antibodies have 
been shown to be more likely to have an infusion reaction 
when compared to those with no antibodies (Menter et al 
2007). However the strength of this relationship is not deﬁ  ni-
tive (Gottlieb et al 2004), and even the proportion of infusion 
reactions in inﬂ  iximab and placebo groups have shown to 
be similar (Reich et al 2005). This issue requires further Biologics: Targets & Therapy 2008:2(1) 120
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Table 2 Open-label, uncontrolled trials of inﬂ  iximab for the treatment of plaque psoriasis
Study Population Dose Duration Results  Adverse  events
Schopf 2002 Moderate to severe 
psoriatic skin lesions 
(n = 8), 2 also had 
PsA
5 mg/kg at 0, 2, and 
6 weeks
14 weeks PASI scores improved by 
88% 
No SAE
Chan 2003 Plaque psoriasis 
(n = 7)
5 mg/kg single dose 
infusion
10 weeks Week 2, average PASI 
improvement: 69%; Week 
10 (n = 4): 89% Week 2, 
DLQI improvement: 61%; 
Week 10 (n = 4): 79%
No SAE
Cassano 
2004
14 diffuse, 13 plaque 
with PsA, 1 eryth-
rodermic, 1 pustular 
(n = 29)
5 mg/kg at 0, 2, 
6, and as-needed 
maintenance 
10 weeks Week 10, PASI 75: 79% 2 infections
Kalb 2005 Severe plaque 
psoriasis >33% BSA 
(n = 52)
5 mg/kg at 0, 2, 
6, 14, and main-
tenance every 
8 weeks 
4–33 months, 
median of 22 
months
88% had at least almost 
clear improvement on PGA 
scale
9 (17%) infusion reactions, 13 
infections
Smith 2006 22 chronic plaque 
psoriasis, 1 pustular 
(n = 23)
5 mg/kg at 0, 2, and 
6 weeks; 3 or 5 
mg/kg maintenance 
dose every 8-10 
weeks 
Up to 21 
months
Week 10, PASI 75: 77% 4 signﬁ  cant elevations in LFTs; 
2 severe systemic infections: 
extrapulmonary tuberculosis 
(splenic abscess) and cellulitis, 
25% discontinued therapy due to 
infusion reactions (2), thrombo-
cytopenia (1), hepatitis (1), renal 
cell carcinoma (1), and CD30+ 
cutaneous T cell lymphoma (1)
Krathen 
2006
Moderate to severe 
plaque psoriasis 
(n = 73)
5 mg/kg at 0, 2, and 
6 weeks; mainte-
nance dose every 
5 to 8 weeks 
At least 12 
months
30% discontinued treat-
ment secondary to loss 
of efﬁ  cacy as determined 
by PGA; 51% no loss of 
efﬁ  cacy
7% experienced minor AE 
leading to discontinuation; 4% 
SAE leading to discontinuation: 
reactivation of TB, breast cancer, 
GI bleeding
Ahmad 
2006
10 chronic plaque 
psoriasis, 1 pustular, 
1 acrodermatitis 
continua (n = 12)
5 mg/kg at 0, 2, 6, 
and maintenance 
every 8 weeks 
  9 had PGA of excellent 
improvement, 2 good PGA 
but became resistant, 1 
failed to respond 
1 infusion reaction, 1 neutrope-
nia, 3 elevated LFT’s
Poulalhon 
2007
20 plaque psoriasis, 
5 psoriatic eryth-
roderma, 3 pustular 
psoriasis (n = 28)
5 mg/kg at 0, 2, and 
6 weeks; mainte-
nance dose every 
8 weeks 
22–185 weeks, 
median of 78 
weeks
Week 14, PASI 75: 68% 18% SAE: delayed infusion 
reaction (1), polyarthralgias (2), 
infectious complications (2) 14% 
severe bacterial infections: com-
munity-acquired pneumonia (2), 
COPD (1), sepsis (1)
Haitz 2007 Chronic plaque 
psoriasis previously 
treated with etaner-
cept (n = 19)
5 mg/kg at 0, 2, 
6, and 14 weeks; 
maintenance dose 
every 14 weeks 
4–25 months, 
median of 8 
months
After 12 to 14 weeks of 
treatment, 89% showed a 
signiﬁ  cant improvement in 
PGA and BSA
47% experienced minor infec-
tions
Abbreviations: AE, adverse events; BSA, body surface area; DLQI, Dermatology Life Quality Index; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; PASI, 
Psoriasis Area and Severity Index; PGA, physician’s global assessment; PsA, psoriatic arthritis; LFTs, liver function tests; SAE, serious adverse events; TB, tuberculosis.
investigation but the potential for subsequent reactions dur-
ing infusion demands close monitoring.
Another concern related to formation of antibodies to 
inﬂ  iximab is the decreased efﬁ  cacy of inﬂ  iximab over time 
which may require increased infusion frequencies or higher 
doses to maintain a clinical response and disease control 
(Haitz and Kalb 2007; Shear 2006). Patients with neutralizing 
antibodies are less likely to maintain a response to inﬂ  iximab Biologics: Targets & Therapy 2008:2(1) 121
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than those negative for antibodies, but this does not determine 
clinical responsiveness (Reich et al 2005; Menter et al 2007). 
When inﬂ  iximab is used in the treatment of Crohn’s disease, 
there is a signiﬁ  cant correlation between the development of 
antibodies against inﬂ  iximab and increased risk of infusion 
reactions and shorter duration of response (Schellekens 
2002). This relationship is much less clear in the treatment 
of plaque psoriasis as no randomized, placebo-controlled 
trials have been performed to date. From our experience, the 
frequency of inﬂ  iximab administration for the treatment of 
plaque psoriasis should be based on clinical response rather 
than antibody status. We have found that when the clinical 
response to inﬂ  iximab is waning, increasing the frequency 
of inﬂ  iximab infusions is more effective than the addition of 
low dose methotrexate.
TNFα inhibition is associated with a lupus-like syndrome, 
which is also thought to be partly the result of an antibody 
response following inﬂ  iximab infusion (Costa et al 2007; 
Ramos-Casals et al 2007). In the aforementioned randomized, 
controlled trials of 378 (Reich et al 2005) and 835 (Menter 
et al 2007) patients with psoriasis, two patients in each study 
had a lupus-like syndrome. It should be noted that in the 
latter case, one patient in the placebo group was diagnosed 
with the syndrome with a 2:1 randomization of inﬂ  iximab 
to placebo (Menter et al 2007).
Inﬂ  iximab’s anti-TNFα effects hamper the immune 
system’s role in defense against infections and malignancies. 
In the clinical use of inﬂ  iximab, infection is the chief 
concern with upper respiratory infections being the most 
common (Gottlieb et al 2003; Reich et al 2005; Menter et al 
2007). In the randomized, controlled clinical studies, there 
is no clinically signiﬁ  cant increase in infection risk with 
inﬂ  iximab compared to placebo (Reich et al 2005; Menter 
et al 2007). Yet, serious infections (Reich et al 2005) and 
malignancies (Gottlieb et al 2004; Reich et al 2005; Menter 
et al 2007) are more prevalent in the inﬂ  iximab groups, 
demonstrating the importance of monitoring for malignancy 
and infection. No additional safety concerns are found for 
the 5 mg/kg dose compared to the 3 mg/kg dose (Menter 
et al 2007).
In individuals undergoing inﬂ  iximab therapy for a variety 
of autoimmune disorders, serious infections have been seen 
with the following agents: Pneumocystis jiroveci, Mycobacte-
rium tuberculosis, Listeria monocytogenes, Candida albicans, 
Aspergillus fumigatus, Histoplasma capsulatum, Cryptococcus 
neoformans, and Coccidioides immitis – infections typical of 
the immunocompromised (Ellerin et al 2003; Kaur and Mahl 
2007). A case of osteomyelitis in a patient without a history of 
trauma who received inﬂ  iximab therapy for severe psoriasis and 
psoriasis arthritis has recently been reported (Sri et al 2007).
Speciﬁ  cally, tuberculosis is a concern as TNFα plays 
a central role in defense against mycobacterial infections 
and containment of existing infections (Gardam et al 2003). 
The reactivation of latent tuberculosis is a well-known 
complication of inﬂ  iximab therapy. A review of 70 cases of 
tuberculosis that developed after the initiation of treatment 
with inﬂ  iximab found that the majority (56%) of patients 
present with extrapulmonary tuberculosis while 24% had 
disseminated disease, forms of tuberculosis associated with 
immunosuppression (Keane et al 2001). These results have 
been reafﬁ  rmed in subsequent clinical trials (Krathen et al 
2006; Smith et al 2006). This atypical presentation as well 
as higher incidence of extensive infection underlines the 
importance of screening for tuberculosis prior to therapy by 
patient history, a tuberculin skin test, a chest radiograph, and 
maintaining a high degree of clinical suspicion throughout 
treatment.
MedWatch received 8 reports of lymphoma in 
approximately 121,000 patients (6.6/100,000) that used 
infliximab between May 1999 and December 2000 for 
rheumatoid arthritis (RA) and Crohn’s disease (CD), with 
the lymphomas occurring within a median of 6 weeks after 
initiation of therapy (Brown et al 2002). It is unclear whether 
the lymphomas developed directly from the use of inﬂ  iximab, 
pre-existing medical conditions, or other immunosuppressive 
agents that the patients were receiving. The aforementioned 
clinical trials of inﬂ  iximab in the treatment of psoriasis 
documented a single case of CD30+ cutaneous T cell lym-
phoma in a patient previously treated with multiple immuno-
suppressive therapies (Smith et al 2006). Thus, the majority 
of data supporting a relationship between inﬂ  iximab therapy 
and lymphoma risk comes from RA and CD patients. The 
risk of lymphoma in psoriasis patients treated with inﬂ  iximab 
has not clearly been established.
Clinical trials have demonstrated a slight increase in 
malignancy in patients treated with inﬂ  iximab. The two 
largest randomized, controlled clinical trials of inﬂ  iximab 
in the treatment of psoriasis found 2% (Menter et al 2007) 
and 1% (Reich et al 2005) of 627 and 298 inﬂ  iximab-treated 
patients experiencing a malignancy, respectively, compared 
to 0 in placebo-treated patients, the majority being skin can-
cers. However, long-term registry data with larger numbers 
of patients have not shown an association between biologic 
therapy and the development of solid tumors or lymphoma. 
There is an association with skin cancers in this registry group 
(Wolfe and Michaud 2007).Biologics: Targets & Therapy 2008:2(1) 122
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Much of the evidence supporting a relationship between 
malignancy and TNFα antagonist therapy is derived from 
the treatment of rheumatoid arthritis patients. A cohort 
study of patients treated with biologic disease-modifying 
antirheumatic drugs (DMARDs) including etanercept, 
inﬂ  iximab, adalimumab, and anakinra for rheumatoid arthritis 
found 11 hematologic malignancies and 46 solid tumors 
during 2940 person-years of DMARD use, and a pooled 
hazard ratio of 1.37 (95% conﬁ  dence interval, 0.71–2.65) and 
0.91 (95% conﬁ  dence interval, 0.65–1.26) for the respective 
malignancies when compared to methotrexate-treated patients 
(Setoguchi et al 2006). A review of nine randomized, placebo-
controlled trials of the use of inﬂ  iximab or adalimumab in 
the treatment of rheumatoid arthritis found a dose-dependent 
increased risk of malignancy in patients treated with anti-TNF 
antibody therapy compared to placebo with a pooled odds 
ratio for malignancy of 3.3 (95% conﬁ  dence interval, 1.2–9.1) 
(Bongartz et al 2006).
Preliminary experimental evidence suggested a link 
between elevated TNFα and congestive heart failure (CHF) 
and that inhibition of TNFα could favorably modify the 
course of the disease (Torre-Amione et al 1996; Feldman 
et al 2000). This theory was discounted when three large-
scale clinical trials of the TNFα inhibitors, inﬂ  iximab 
(Chung et al 2003a) and etanercept (Anker and Coats 2002), 
used in the treatment of CHF were halted for lack of beneﬁ  t 
or adverse outcomes. The inﬂ  iximab trial revealed that short-
term inﬂ  iximab therapy did not improve patients with CHF, 
and high doses (10 mg/kg) adversely affected patients with 
CHF (p = 0.043) (Chung et al 2003b). MedWatch data also 
suggest that TNFα antagonists may induce heart failure in 
certain patients (Kwon et al 2003). No adverse cardiac events 
were reported in the trials of patients receiving inﬂ  iximab 
therapy for psoriasis (Tables 1 and 2).
Inﬂ  iximab is associated with cases of central nervous 
system involvement including rare demyelinating disorders 
(Mohan et al 2001; Robinson et al 2001). The clinical tri-
als of inﬂ  iximab in the treatment of psoriasis found that no 
cases of CNS disease resulted from this therapy (Tables 1 
and 2). The causal relationship is weak if it exists at all, 
but it is recommended that the use of inﬂ  iximab and other 
TNFα antagonists be avoided in patients with a history of 
demyelinating disease, and that therapy be discontinued when 
neurologic symptoms occur.
Elevations in serum ALT and AST are fairly commonly 
reported (Tables 1 and 2), but associated hepatobiliary 
problems are much less frequent. In a letter to healthcare 
professionals regarding the potential of hepatotoxicity 
due to infliximab therapy, the US FDA reported 35 
post-marketing and 3 clinical trial events of severe 
hepatitic reactions including acute liver failure, jaundice, 
autoimmune hepatitis, and cholestasis (Important drug 
warning 2004). In clinical trials of the use of inﬂ  iximab in 
plaque psoriasis reviewed here (Tables 1 and 2), a single 
case of autoimmune hepatitis due to inﬂ  iximab was reported 
in a patient previously diagnosed with fatty liver (Smith 
et al 2006). Hepatitis has also been reported in a patient 
undergoing inﬂ  iximab therapy for psoriasis in the absence 
of autoimmune disease and previous liver damage (Wahie 
et al 2006). In both patients, previous methotrexate use and 
alcohol consumption are contributing factors. It is thought 
that concurrent methotrexate and inﬂ  iximab therapy may 
exert synergistic effects on liver function, underlying the 
importance of close monitoring of liver function tests, 
especially in patients with a history of methotrexate use 
and alcohol consumption.
The extensive clinical trials and cases referenced above as 
well as physician experience has allowed the detection of the 
aforementioned rare adverse events. More long-term safety 
data has to be collected to establish a deﬁ  nitive relationship 
between these adverse events and inﬂ  iximab in the treatment 
of psoriasis. Inﬂ  iximab has generally been well tolerated in 
the more than 924,000 patients that have received infusions 
(Remicade 2007).
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